Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases
Aim: This retrospective study investigated real-world hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) treatment patterns in pediatric patients with primary immunodeficiency diseases (PIDs) in Poland. Methods: Clinical and demographic information, fSCIG treatment parameters and clinical outcomes were extracted from medical records of 28 participants (aged ≤18 years) with PIDs who received fSCIG. Results: 18 participants (64.3%) started fSCIG with a ramp-up (median duration: 35.5 days). 27 patients (96.4%) were administered fSCIG every 4 weeks and one patient every 3 weeks. 25 patients (89.3%) used one infusion site. No serious bacterial infections occurred. Conclusion: Data support the feasibility of administering fSCIG to children and adolescents with PIDs every 3-4 weeks using a single infusion site and indicate flexibility in modifying fSCIG infusion parameters. Clinical Trial Registration: NCT04636502 (ClinicalTrials.gov).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Immunotherapy - 16(2024), 6 vom: 29. Apr., Seite 391-403 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mach-Tomalska, Monika [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 02.04.2024 published: Print-Electronic ClinicalTrials.gov: NCT04636502 Citation Status MEDLINE |
|---|
| doi: |
10.2217/imt-2023-0305 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368527123 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368527123 | ||
| 003 | DE-627 | ||
| 005 | 20240403000241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240216s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/imt-2023-0305 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1361.xml |
| 035 | |a (DE-627)NLM368527123 | ||
| 035 | |a (NLM)38362629 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mach-Tomalska, Monika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 02.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04636502 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: This retrospective study investigated real-world hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) treatment patterns in pediatric patients with primary immunodeficiency diseases (PIDs) in Poland. Methods: Clinical and demographic information, fSCIG treatment parameters and clinical outcomes were extracted from medical records of 28 participants (aged ≤18 years) with PIDs who received fSCIG. Results: 18 participants (64.3%) started fSCIG with a ramp-up (median duration: 35.5 days). 27 patients (96.4%) were administered fSCIG every 4 weeks and one patient every 3 weeks. 25 patients (89.3%) used one infusion site. No serious bacterial infections occurred. Conclusion: Data support the feasibility of administering fSCIG to children and adolescents with PIDs every 3-4 weeks using a single infusion site and indicate flexibility in modifying fSCIG infusion parameters. Clinical Trial Registration: NCT04636502 (ClinicalTrials.gov) | ||
| 650 | 4 | |a Clinical Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a facilitated subcutaneous immunoglobulin | |
| 650 | 4 | |a hyaluronidase | |
| 650 | 4 | |a inborn errors of immunity | |
| 650 | 4 | |a pediatric | |
| 650 | 4 | |a primary immunodeficiency disease | |
| 650 | 4 | |a real-world | |
| 650 | 7 | |a Hyaluronoglucosaminidase |2 NLM | |
| 650 | 7 | |a EC 3.2.1.35 |2 NLM | |
| 650 | 7 | |a Immunoglobulins |2 NLM | |
| 700 | 1 | |a Pituch-Noworolska, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Bień, Ewa |e verfasserin |4 aut | |
| 700 | 1 | |a Malanowska, Magdalena |e verfasserin |4 aut | |
| 700 | 1 | |a Machura, Edyta |e verfasserin |4 aut | |
| 700 | 1 | |a Pukas-Bochenek, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Chrobak, Ewelina |e verfasserin |4 aut | |
| 700 | 1 | |a Pac, Małgorzata |e verfasserin |4 aut | |
| 700 | 1 | |a Pietrucha, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Drygała, Szymon |e verfasserin |4 aut | |
| 700 | 1 | |a Kamieniak, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Kasprzak, Jakub |e verfasserin |4 aut | |
| 700 | 1 | |a Heropolitańska-Pliszka, Edyta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Immunotherapy |d 2009 |g 16(2024), 6 vom: 29. Apr., Seite 391-403 |w (DE-627)NLM19257163X |x 1750-7448 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g number:6 |g day:29 |g month:04 |g pages:391-403 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/imt-2023-0305 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |e 6 |b 29 |c 04 |h 391-403 | ||